Premium
NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY
Author(s) -
Ansell S. M.,
Bröckelmann P. J.,
Keudell G.,
Lee H. J.,
Santoro A.,
Zinzani P. L.,
Collins G. P.,
Cohen J. B.,
Boer J. P.,
Kuruvilla J.,
Savage K. J.,
Trneny M.,
Provencio M.,
Jaeger U.,
Willenbacher W.,
Swanink R.,
Sacchi M.,
Shipp M. A.,
Engert A.,
Armand P.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.74_2879
Subject(s) - medicine , nivolumab , cohort , clinical endpoint , oncology , refractory (planetary science) , progression free survival , transplantation , brentuximab vedotin , surgery , gastroenterology , lymphoma , chemotherapy , cancer , immunotherapy , clinical trial , hodgkin lymphoma , astrobiology , physics